Ketorolac-fluconazole: A New Combination Reverting Resistance in Candida albicans from Acute Myeloid Leukemia Patients on Induction Chemotherapy: In vitro Study

Background and Objectives: Candida albicans is a significant source of morbidity and mortality for patients with acute myeloid leukemia (AML). Prolonged use of fluconazole as empirical antifungal prophylaxis in AML patients leads to overexpression of efflux pump genes that resulted in the emergence of azole-resistant species. Consequently, the introduction of a new strategy to improve the management of C. albicans infections is an urgent need. Nonsteroidal anti-inflammatory drug (NSAID) ketorolac is associated with a reduction in cancer relapses. The present study was performed to investigate the use of ketorolac-fluconazole combination to reverse fluconazole resistance in C. albicans isolated from AML patients on induction chemotherapy.

Patients and Methods: One hundred and seventy AML patients were evaluated. Fifty C. albicans were isolated and subjected to disc diffusion assay and broth microdilution for fluconazole alone and combined with different concentrations of ketorolac. Efflux pump gene (CDR1, CDR2, and MDR1) expressions were quantified by real-time PCR.

Results: The tested ketorolac acted synergistically with fluconazole against resistant C. albicans with the minimum inhibitory concentration (MIC) of fluconazole decreased from >160 μg/mL to 0.3–1.25 μg/mL in (93.8%) of resistant isolates with fractional inhibitory concentration index (FICI) value of 0.25. The majority of the resistant isolates overexpressed CDR1 (71.1%) and MDR1 (60%).

Conclusion: Ketorolac-fluconazole in vitro combination would be a promising strategy for further clinical in vivo trials to overcome fluconazole resistance in AML patients on induction chemotherapy.

Keywords: ketorolac, fluconazole resistance, acute myeloid leukemia, CDR1, MDR1

Introduction

Acute myeloid leukemia (AML) is a hematological disease caused by the clonal expansion of myeloblasts in the peripheral blood, bone marrow, or other tissues. It is characterized by various chromosomal abnormalities and gene mutations. The typical clinical manifestations of AML are fever, fatigue, and bleeding caused by the expansion of blasts and decreased normal hematopoiesis in the bone marrow. Treatment of AML by combination chemotherapy results in persistent neutropenia, which further increases the risk of opportunistic infections. Candida spp. is an important opportunistic human pathogen that causes oropharyngeal candidiasis (OPC), vulvovaginitis, and invasive infections in AML.
patients. The of American Infectious Diseases Society has approved fluconazole as a primary drug of choice for prophylaxis and treatment of candidiasis.

Fluconazole has several advantages over other antifungal drugs including the safety, oral bioavailability, cost, and ability to cross the blood–brain barrier. Fluconazole inhibits the cytochrome P450 enzyme lanosterol demethylase, a critical enzyme in the synthesis of ergosterol which is encoded by the ERG11 gene. However, the extensive use of fluconazole as empirical therapy in cancer patients, especially in AML patients, has increased the incidence of resistance to the drug among different fungal strains, especially Candida albicans. Fluconazole resistance has the potential to cross over to other azoles including voriconazole and itraconazole.

There are multiple mechanisms for azole resistance, the major one is overexpression of plasma membrane efflux pumps. The ATP-binding cassette (ABC) pumps and the major facilitator superfamily (MFS) transporters are the two main families of efflux proteins. They differ in the source of energy used for their activity and encoded by Candida drug resistance (CDR1 and CDR2) and multidrug resistance (MDR1) genes. They are located in the plasma membrane and are responsible for pumping the drug out of the fungal cell decreasing its intracellular concentration which leads to treatment failure.

Several studies have stated the ability of some drugs to reverse azole resistance in C. albicans. Generally, these drug concentrations required to reverse the azole resistance are above the therapeutic concentrations. Moreover, some of these drugs can result in serious side effects, such as those caused by cyclosporine and tacrolimus. Remarkably, a few studies have reported the ability of some nonsteroidal anti-inflammatory drugs (NSAIDs) to act synergistically with different antifungals. For example, ibuprofen was found to exhibit synergistic activity with azoles against Candida spp. NSAIDs have antipyretic, analgesic, and can be used alone or in combination with other drugs for the treatment of cancer. They also have direct and indirect antimicrobial effects. The antifungal activities of NSAIDs against Candida spp. include the reduction of extracellular polysaccharide, hyphal, and biofilm formations.

To repurpose drugs and explore new leads in the field of antifungal drug discovery; we explored another nonsteroidal anti-inflammatory drug “ketorolac” to reverse azole resistance in C. albicans. Ketorolac is a potent analgesic, antipyretic, and moderate anti-inflammatory drug used in the treatment of severe cancer pain. The simple use of this safe and effective anti-inflammatory agent might eliminate most early cancer relapses.

In the current study, we investigate a new strategy to improve the management of C. albicans infections through the use of in vitro ketorolac-fluconazole in combination to reverse fluconazole resistance in C. albicans isolated from AML patients and overexpressing efflux pumps genes (CDR1, CDR2, and MDR1) assessed by quantitative real-time qRT-PCR.

Materials and Methods

Ethical Statement

This study was approved by the Local Ethics Committee (no. 17100543), Faculty of Medicine, Assiut University in accordance with the provisions of the Declaration of Helsinki. Informed written consent was obtained from all patients before enrolment in the study.

Patients

This study included 170 AML patients admitted from October 29, 2016, to March 11, 2020, to the Department of Internal Medicine (Hematology Unit), and South Egypt Cancer Institute (SECI) in Assiut University, Assiut, Egypt. All newly diagnosed non-M3 AML patients (aged 18–69 years) were enrolled in this study. The patients were diagnosed according to the WHO criteria for AML. Standard induction chemotherapy for 170 non-M3 AML patients in this study was idarubicin 12 mg/m²2 per day for two to three days, and cytarabine 100 mg/m²2/day for five to seven days. Patients received prophylactic treatment during the period of neutropenia following chemotherapy in the form of sulfamethoxazole (400 mg/trimethoprim 80 mg once or twice daily). Patients received empirical azole prophylaxis, fluconazole (400 mg PO/IV per day).

During induction chemotherapy, granulocyte colony-stimulating factor (G-CSF) was used in a few cases showing poor performance status and not applied routinely for all patients. The definition of treatment response generally followed the European Leukemia Network (ELN) 2010 recommendation. Complete remission (CR) was defined as a blast count less than 5% in the bone marrow. Partial remission (PR) was defined as a decrease in bone marrow blasts by 50% but still remaining in a range of 5–25%. Resistant disease (RD) was referred to those who failed to achieve CR or PR in bone marrow examination after chemotherapy. The undefined response was referred to
those who had no available results of bone marrow examination after chemotherapy. Exclusion criteria including AML (M3), AML with antecedent hematologic malignancy, Patients with possible risk factors of candidiasis, such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) positive, diabetes, and autoimmune diseases. Patients with contraindication to fluconazole therapy as abnormal heart rhythm, prolonged QT interval on EKG, abnormal liver function tests, pregnancy, and chronic kidney disease: moderate to severe stage. Data were collected and included the following parameters: age, gender, and, cytogenetic results at diagnosis, induction regimens, and treatment response, Table 1.

**Standard Control Strain**

*C. albicans* ATCC 10231 was obtained from MIRCIN culture collection of the Faculty of Agriculture, Ain Shams University, Egypt.

**Clinical Sample Collection and Processing**

Samples collected from the patients according to their clinical presentation and different localizing symptoms. Vaginal swabs from patients with vaginal infection. Oropharyngeal swabs from patients with oral thrush were rubbed on the candidiasis lesion. Swabs were streaked on Sabouraud dextrose agar medium supplemented with chloramphenicol (0.5 g/L) (SDA, HiMedia, India) and incubated at 30°C for 48 h. *Candida* spp. shows typical creamy white pasty colonies with characteristic yeasty odor. Each isolated *Candida* spp. was individually stored at −20°C with 20% glycerol.

**Phenotypic Identification of Candida albicans Strains**

(a) Germ tube test: by inoculating yeasts in small tubes containing 0.5 mL of human serum (Sigma-Aldrich, Germany) containing 0.5% glucose and incubated at 37°C for two to three hours. It is positive for *C. albicans* or *C. dubliniensis*.

(b) Corn meal agar (CMA): by inoculating yeasts on CMA containing Tween 80 (Difco, USA), for four to seven days to ensure production of chlamydospores. It is positive for *C. albicans* or *C. dubliniensis*.

(c) CHROMagar® *Candida* medium: (CHROMagar, Paris, France) which allows selective isolation and identification of *C. albicans*, *C. dubliniensis*, *C. tropicalis*, and *C. krusei* by morphology and color reaction. The strains were identified as *C. albicans* or *C. dubliniensis* for green colonies, *C. tropicalis* for steel blue colonies, *C. krusei* colonies showing rose color.

(d) Growth at 45°C: Growth at 45°C has been considered a useful test for the differentiation of *C. dubliniensis* (no growth) from *C. albicans* (growth).

(e) Sugar assimilation test: using API 20C AUX (bioMérieux SA, France) according to the manufacturer’s instructions.

**Genotypic Identification of Candida albicans Strains by Polymerase Chain Reaction (PCR)**

The species specific primer pair sequence for the amplification of the 25S rRNA gene was described by Mannarelli and Kurtzman: (5’ TGTTGCTCTCTCGGGGGCGGCGG 3’ and 5’ AGATCATTATGCGCCAACATCCTAGGT TAA 3’).
A 3'). It is specific for *C. albicans* and amplifies a 175-bp DNA fragment. DNA extraction was done by a commercial QIAamp DNA Mini Kit (Qiagen, Germany). DNA amplification performed using the Thermocycler T100 gradient system (BioRadT100, USA). PCR reaction mixture and PCR amplification conditions were performed according to the method described by Marinho et al. Amplification product visualized by electrophoresis on 2% agarose gel using a 100-bp ladder molecular weight ladder (Gen Ruler 100bp DNA ladder plus).

**Antifungal Susceptibility Test**

**Disk Diffusion Method**

Adopted by the Clinical and Laboratory Standards Institute (CLSI), the M44-A2 protocol was used to evaluate the degree of fungal sensitivity for four common azoles. Antifungal discs were obtained from (HiMedia, India). The response to the antifungal agents was determined via the interpretive breakpoints described in Table 2.

**Determination of MICs by Broth Microdilution**

The MICs of fluconazole (Sigma, USA) and ketorolac (Sigma, USA) separately were identified by the protocol recommended by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). The test was conducted in 96-well microtiter plates with yeast (2.5×10⁵ CFU/mL) in RPMI-1640 medium (PH 7.0) buffered with MOPS (Sigma, USA) and supplemented with glucose to a final concentration of 2%. RPMI-1640 containing wells were considered negative controls, and a drug-free well was set as a growth control. After 24 h of incubation at 35°C, MICs were determined as described above. To evaluate the intensity of the drug interactions, the fractional inhibitory concentration index (FICI) model was used to analyze the obtained data. The FICI model is based on the Loewe additivity theory and is expressed as $FICI = \frac{FIC_A + FIC_B}{(A/MIC_A) + (B/MIC_B)}$ where A and B are the MIC of each drug in combination (in a single well), and MICₐ and MICₐ are the MIC of each drug individually. The drug interaction is interpreted as synergistic when $FICI \leq 0.5$, indifferent when $FICI >0.5–4.0$, and antagonistic when $FICI >4.0$.

**Efflux Pump Genes Expression Analysis by qRT-PCR**

**Reverse Transcriptase (RT)-PCR**

The reverse transcription was performed using HiSenScript™ RH(-) cDNA Synthesis Kit (iNtRON, Cat. no. 25014) according to the manufacturer’s instructions.

**Table 2 Interpretative Breakpoints of Disk Diffusion Method for Fluconazole, Itraconazole, Miconazole, and Voriconazole**

| Antifungal | Abbr. | Conc./Disc | Zone Diameter in mm |
|------------|-------|------------|---------------------|
| Fluconazole | FU    | 25 µg      | ≥19, 15–18          |
| Itraconazole | IT    | 10 µg      | ≥23, 14–22          |
| Miconazole | MIC   | 10 µg      | ≥20, 12–19          |
| Voriconazole | VRC  | 1 µg       | ≥17, 14–16          |

**Abbreviations:** S, susceptible; I, intermediate; R, resistant.

MIC interpretive criteria of fluconazole for *C. albicans* were those described in the document E.DEF 7.3.1 [available on the EUCAST website: http://www.eucast.org]. MIC $\leq2.0$ mg/L was considered to be sensitive, MIC between 2.0 and 4.0 mg/L was considered to be intermediate and that >4.0 mg/L was considered resistant.
Reverse transcription was performed at 45°C for 60 min, followed by 80°C for 10 min. The cDNA products were stored at −20°C for later use as templates for quantitative real-time PCR (qRT-PCR).

**Real-Time PCR**

The procedures of qRT-PCR analysis were described in a previous study. Expression levels of the target genes (CDR1, CDR2, and MDR1) and the housekeeping gene (ACT1, used as a normalizing gene) were assessed by quantitative real-time RT-PCR (qRT-PCR). The primers (analysis) used tested through the BLAST program (http://www.ncbi.nlm.nih.gov/BLAST) and listed in Table 3. The expression of target genes was carried out using SensiFAST SYBR® No-ROX (Bioline, USA) using a 7500 Fast Real-Time PCR System (Applied Biosystems). The fold change in expression of these genes was calculated according to the 2^(-ΔΔCT) method using ACT1 as a control gene to normalize cDNA levels.

Fluconazole-susceptible *C. albicans* clinical isolate (MIC, 0.5 mg/L) was used as a reference isolate for gene expression analysis. Real-time PCR reaction mix for (CDR1, CDR2, MDR1 and ACT1) contained 0.5 μL of cDNA, 1.5 μL of 2 μm primer and 7.5 μL of 2×SYBR Green Master Mix in a final volume of 15 μL and qRT-PCR was performed using the following cycling conditions: 95°C for 10 min, 40 cycles of 95°C for 15 seconds, 50°C for 15 seconds for CDR1, CDR2, and ACT1, or 55°C for 15 seconds for MDR1, and 60°C for 30 seconds.

**Statistical Analysis**

Data entry and data analysis get done using SPSS (Statistical Package for Social Science) version 19. Data were presented as a number, percentage, mean, median, standard deviation, and standard error. Chi-squared test and Fisher’s exact test were used for comparing qualitative variables. The Mann–Whitney U-test was used to compare nonparametric tests. *P*-value considered statistically significant when *P*-value <0.05.

**Results**

**Patient Population**

The demographic and clinical characteristics of 170 non-M3-AML patients who received induction chemotherapy admitted to Clinical Hematology Unit, Internal Medicine Department, Assiut University Hospital, and South Egypt Cancer Institute (SECI) presented in Table 1. The median age was 49 years (range: 18–69 years). Female patients were 72 (42.35%) while male patients were 98 (57.65%). The diagnosis was performed according to the WHO criteria for AML. There were mainly AML M4, AML M2, AML M1 and AML M5 (51 (30%), 49 (28.82%), 33 (19.41%) and 19 (11.17%) respectively. A total of 39 patients (22.9%) had favorable cytogenetic risk, 74 (43.52%) intermediate cytogenetic risk, and 41 (24.11%) unfavorable risk.

The collected samples were 76 oropharyngeal swabs, 42 vaginal swabs. Seventy-five samples were diagnosed as yeast infection from which 50 isolates were diagnosed as *Candida albicans* by phenotypic tests and PCR.

**Antifungal Susceptibility Test**

**Disk Diffusion Method**

The pattern of antifungal resistance to tested azoles for *Candida albicans* isolates was relatively high 94% for both fluconazole and voriconazole, 74% for miconazole and itraconazole as shown in Table 4.

**Ketorolac Acted Synergistically with Fluconazole Against Resistant *C. albicans* in vitro**

The minimal inhibitory concentrations (MICs) of ketorolac and fluconazole against resistant *C. albicans* are listed in Table 5. The MIC of fluconazole was all >160 μg/mL for 94% of tested *C. albicans* isolates, indicating strong resistance of these *C. albicans* isolates. The MIC of ketorolac was >10 μg/mL. However, when used in combination with fluconazole, ketorolac could significantly decrease the MICs of fluconazole from >160 μg/mL to 0.3–1.25 μg/mL, indicating a significantly increased sensitivity of resistant *C. albicans* to fluconazole caused by ketorolac. When the MIC of FLC was decreased to <2 μg/mL, the

---

**Table 3** Gene-specific Primers Used for RT-qPCR

| Gene | Primer Sequence                  |
|------|----------------------------------|
| CDR1 | F: 5′-TGCCAAACAATCCAACAAC-3′     |
|      | R: 5′-CGACGATCCCTTCATGACA-3′     |
| CDR2 | F: 5′-AAGGTTCGTAGCTACTGC-3′      |
|      | R: 5′-GTCGGGAGAGTTGTAG-3′        |
| MDR1 | F: 5′-GTTGTGGCCATTGTTTCCAGT-3′   |
|      | R: 5′-CCAAAGCA GTGGGAGATTGTAG-3′ |
| ACT1 | F: 5′-AAAATGGATTGCGCTGTGAGAGA-3′|
|      | R: 5′-TGCCGAAAGATTGAGAAGTGT-3′  |
concentration of ketorolac required was 2.5 μg/mL. Moreover, the FICI values obtained from the FICI model were <0.5, showing a strong synergism induced by ketorolac plus fluconazole.

**Efflux Pump Genes Expression Analysis**

CDR1, CDR2, and MDR1 gene expression levels were quantified for all 50 isolates and normalized relative to the housekeeping gene, ACT1. This study found that the MDR1 gene showed the most gene overexpression (88%) followed by CDR1 gene (84%), and finally CDR2 gene (12%). When comparing the relationship between fluconazole MICs and the expression of efflux-related genes (Figure 1), it was clear that isolates with higher fluconazole MIC (>4.0 mg/L) showed higher expression levels of CDR1 and MDR1, Table 6. These results confirm those expression levels of efflux-related genes CDR1 and MDR1 agree with fluconazole MICs in the C. albicans isolates.

**Discussion**

In Egypt, leukemia comprises (10%) all malignancies, with AML representing (16.9%). This study included 170, non-M3 (acute promyelocytic) AML patients. The ages ranged from 18 to 69 years, with a mean of 49 years. A slight male predominance was noted (female to male ratio was 1:1.36). The commonest FAB subgroup was M4 followed by M2. Another study at National Cancer Institute (NCI)-Egypt on 82 adult AML patients showed epidemiological characteristics of AML Egyptian patients, slightly similar to our data. Their ages ranged between 18 and 68 years with a median of 34 years. The male to female ratio was 1.05:1, and the commonest FAB subgroups reported were M1 and M2.

Another Egyptian study included ninety AML patients. The ages ranged from 18 to 76 years, with a mean of 37.8 years. A slight female predominance was noted (male to female ratio was 1:1.3). The commonest FAB subgroup was M2 followed by M5.

Response of induction chemotherapy in the current study, were complete remission (CR), partial remission, resistant disease and undefined response: 81 (47.64%), 20 (11.76%), 46 (27.05%) and 23 (13.52%), respectively. The time elapsed between presentation and start of treatment ranged from 4 to 85 days, with a mean of 13 days. The treatment delay in most patients of our study was mainly due to uncontrolled infection. An Egyptian study showed CR achievement in (57.5%) of AML patients, which is a slightly higher rate than that of our study. It can be explained that we adopted treatment strategy interruption with neutropenic fever onset, which reduced treatment-related mortality at the expense of response rate. Also, slightly longer duration from onset of presentation to treatment beginning when compared with such study.

A retrospective study on 1317 AML patients had time elapsed between presentation and start of treatment with a median of four days, and a range of 1–78 days. The longer time was associated with worse CR in patients younger than 60 years, and this effect was more pronounced with duration of five days or more. It is crucial that public health systems in developing countries (DC), including

| Table 4 Resistance Patterns of 50 C. albicans Using a Kirby–Bauer Disk Diffusion Method for Azoles |
|--------------------------------------------------------|
| **Total (n= 50)** | Fluconazole (25 μg/Disc) | Miconazole (10 μg/Disc) | Voriconazole (1 μg/Disc) | Itraconazole (10 μg/Disc) |
| **N (%)** | **N (%)** | **N (%)** | **N (%)** | **N (%)** |
| Sensitive (S) | 3 (6) | 3 (6) | 3 (6) | 3 (6) |
| Intermediate (I) | 0 (0) | 10 (20) | 0 (0) | 10 (20) |
| Resistant (R) | 47 (94) | 37 (74) | 47 (94) | 37 (74) |

**Note:** Data are presented as number (%) of isolates resistant to antimicrobial indicated.

| Table 5 In vitro Interaction of Ketorolac with Fluconazole Against Resistant C. albicans |
|--------------------------------------------------------|
| **Mean MIC (μg/mL)** | **Mean MIC (μg/mL)** | **Mean FICI** | **IN** |
| **Ketorolac** | **Fluconazole** | **Ketorolac** | **Fluconazole** | **Ketorolac** |
| >10 | >160 | 2.5 | 0.62 | 0.25 | SYN |

**Abbreviations:** IN, interpretation; SYN, synergism.
Egypt, turn to larger epidemiological studies to better understand how the disease characteristics interact with socioeconomic factors. An appropriate health system must shorten the time from diagnosis to treatment to ensure a better outcome of induction therapy and more successful result in AML.

*C. albicans* is an important cause of morbidity and mortality for AML patients. The rise of multidrug resistant organisms causes a challenge in the treatment of infective diseases. Resistance among *C. albicans* represents a serious therapeutic problem that is mainly attributed to the overexpression of efflux pump genes encoded by *CDR1*, *CDR2* (related to azole cross-resistance), and *MDR1* genes (confined to selective resistance to fluconazole). In our study, in vitro susceptibility testing for *C. albicans* isolated from AML patients to four azoles using disc diffusion method showed a high level of resistance pattern that was 94% for both fluconazole and voriconazole, 74% for miconazole and itraconazole. Also, the MIC of fluconazole was all >160 μg/mL for 94% of tested *C. albicans* isolates, indicating a very high resistance of these *C. albicans* isolates, which is consistent with 86.2% and

![Figure 1 Efflux pump gene expression of C. albicans isolates in relation to the MIC of fluconazole.](https://doi.org/10.2147/JBM.S302158)
75.9 fluconazole resistance among *C. albicans* isolated in two recent local studies in Egypt, respectively. 39,40

All the MICs obtained to support the antibiogram of isolates to fluconazole, which indicates that disk diffusion has a good correlation with MIC. Pfäffer et al showed similar results. 41

Many researchers indicated that prolonged therapy and increased use of antifungals for prophylaxis or treatment of recurrent candidiasis are the most common risk factors to azole resistance. 42 To overcome fungal resistance, research on antifungal sensitizers has attracted considerable attention. 43

The need for novel antifungal regimens to overcome resistance prompted us to study the activity of ketorolac, which has a superior effect on pain control in cancer patients that suffer from frequent and recurrent *Candida* infections which showed a high level of resistance to the most common group of antifungals, the azoles, especially fluconazole.

In vitro, we found that ketorolac acted synergistically with fluconazole against tested *C. albicans* isolates, as interpreted by the FICI as it decreased the MIC of fluconazole by >4 folds against 93.6% of resistant isolates (new finding). This is superior to the recently reported 60.9% reversal of fluconazole resistance using ibuprofen by Sharma et al. 44

The MIC of ketorolac was >10 μg/mL. However, when used in combination with fluconazole, ketorolac could significantly decrease the MICs of fluconazole from >160 μg/mL to 0.3–1.25 μg/mL, indicating a significantly increased sensitivity of resistant *C. albicans* to fluconazole caused by ketorolac. When the MIC of FLC was decreased to <2 μg/mL, the concentration of ketorolac required was 2.5 μg/mL. Similar study on the combination of ibuprofen with fluconazole showed synergic activity in 8/12 of studied *Candida spp.* including four of the five fluconazole-resistant strains. The MICs of fluconazole in fluconazole-resistant *Candida spp.* decreased 2 to 128-fold when the drug was associated with ibuprofen. Also the MICs for ibuprofen decreased 64-fold for the 12 studied *Candida spp.* They reported the practicability of using ibuprofen in combination with fluconazole in the treatment of *Candida* infections. 14

The continuous emergence of resistance to conventional drugs through efflux pumps leads to increasing efforts directed toward discovering efflux inhibitory molecules. 45 This study found that the MDR1 gene was the gene that showed the most overexpression (88%) followed by *CDR1* gene (84%), and finally *CDR2* gene (12%). This finding is suggesting that *CDR1* protein contributes more than *CDR2* protein in resistance by ABC family of efflux pump which agreed with the finding of Tsao et al, 46 and Holmes et al who conclude that in *C. albicans* Cdr1p efflux activity makes a greater contribution than Cdr2p to resistance to fluconazole and Cdr1p was present in greater amounts (2 to 20-fold) than Cdr2p. This result was contradictory with Chau et al who found that *CDR2* was overexpressed in the majority of the patient isolates. This can be explained by that reported by Niimi et al who found that the strains hyperexpression *CDR2* showed decreased susceptibility to caspofungin in agar plate drug resistance assays because ABC transporters confer resistance to a wide range of structurally unrelated xenobiotics so *CDR2* may be related to other antifungal resistance.

In three *C. albicans* isolates, although their resistance profile to fluconazole, they exhibited downregulation of genes of efflux pump which suggested different azole resistance mechanisms as those belonging to ERG11 which was described. 39

### Conclusion

To our knowledge, the current study is the first in vitro report on the use of ketorolac in reverting fluconazole resistance in

### Table 6 The Level of the Efflux Pumps Gene Expression in Resistant and Sensitive Strains in the Human Study Group

| Gene   | Mean ±SE   | Median | P-value |
|--------|------------|--------|---------|
| *CDR1* |            |        |         |
| Resistant strains | 11.16±0.9 | 11.02  | 0.006** |
| Sensitive strains  | 0.13±0.12 | 0.13   |         |
| *CDR2* |            |        |         |
| Resistant strains | 0.33±0.07 | 0.1    | 0.078*  |
| Sensitive strains  | 0.02±0.003| 0.02   |         |
| *MDR1* |            |        |         |
| Resistant strains | 7.81±0.96 | 5.88   | 0.004***|
| Sensitive strains  | 0.37±0.003| 0.04   |         |

**Notes:** *Nonsignificant (P>0.05), *significant (P<0.05), **highly significant (P<0.005).
C. albicans isolated from AML patients. Resistance of C. albicans to azole antifungals is associated with overexpression of efflux pump genes especially CDRI and MDRI. Ketorolac concentration as low as (2.5 μg/mL) was able to revert resistance in 93.8% of tested strains, so the current study recommends for the next step to run clinical studies based on the in vivo ketorolac-fluconazole combination therapy for AML patients.

**Data Sharing Statement**
The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Acknowledgments**
We acknowledge the Medical Research Center, Faculty of Medicine, Assiut University, for providing the necessary laboratory equipment for carrying out the experiments.

**Author Contributions**
All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

**Funding**
This research was funded by the Grant Office, Faculty of Medicine, Assiut University, (Grant Code: 2019-01-16-001).

**Disclosure**
Dr Shereen A Sayed and Dr Hayam H Mohammed report grants from Faculty of Medicine Assiut University, during the conduct of the study. Dr Ehsan AB Hassan reports that a grant was obtained from Faculty of Medicine, Assiut University, for all the authors in this study. The authors declare no other potential conflicts of interest in this work.

**References**
1. Grove CS, Vassiliou GS. Acute myeloid leukemia: a paradigm for the clonal evolution of cancer? *Dis Model Mech.* 2014;7(8):941–951.
2. Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard dose idarubicin with high dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML 201 study. *Blood.* 2011;117:2358–2365. doi:10.1182/blood-2010-03-273243
3. Wang ES. Common fungal infection in patients with leukemia. *Clin Adv Hematol Oncol.* 2017;5(15):352.
4. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Disease Society of America. *Clin Infect Dis.* 2016;62(4):e1–e50.
5. Shao PL, Huang LM, Hsueh PR. Recent advances and challenges in the treatment of invasive fungal infection. *Int J Antimicrob Agents.* 2007;30(6):487–489. doi:10.1016/j.ijantimicag.2007.07.019
6. Paul S, Kannan I, Mohanram K. Extensive ERG11 mutation associated with fluconazole-resistant Candida albicans isolated from HIV infected patients. *Curr Med Mycol.* 2019;5(3):1.
7. Goncalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. Epidemiology and molecular mechanism of antifungal resistant in Candida and Aspergillus. *Mycokeys.* 2016;59(4):198–219.
8. Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanism and clinical impact. *Clin Infect Dis.* 2008;46(1):120–128. doi:10.1086/524071
9. Rogers PD, Barker KS. Genome wide expression profile analysis reveals coordinately regulated genes associated with stepwise acquisition of azole resistance in Candida albicans clinical isolates. *Antimicrob Agents Chemother.* 2003;47(4):1220–1227. doi:10.1128/AAC.47.4.1220-1227.2003
10. Akins RA. An update on antifungal target and mechanism of resistance in Candida albicans. *Med Mycol.* 2005;43(4):285–318. doi:10.1080/13693780500138971
11. Liu S, Yue L, Gu W, Li X, Zhang L, Sun S. Synergetic effect pfluconazole and calcium channel blocker against resistant Candida albicans. *PLoS One.* 2016;11(3):e0150859. doi:10.1371/journal.pone.0150859
12. Chen X, Ren B, Chen M, et al. ASDCD:Antifugal synergistic drug combination database. *PLoS One.* 2014;9(4):e86499. doi:10.1371/journal.pone.0086499
13. Rodrigues-Diez R, Gonzales-Guerrero C, Ocana-Salceda C, et al. Calcinurin inhibitors cyclopamine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. *Sci Rep.* 2016;6(1):1–16. doi:10.1038/s41598-016-0001-8
14. Pina-vaz C, Sansoneetty F, Roderigues AG, Martinez-de-oliveria J, Fonseca AF, Mardh P-A. Antifungal activity of ibuprofen alone, and in combination with fluconazole against candida species. *J Med Microbiol.* 2000;49(9):831–840. doi:10.1099/0022-1317-49-9-831
15. Hersh E, Hammond B, Fleury A. Antimicrobial activity of flurbiprofen, and ibuprofen in vitro against six common periodontal pathogens. *J Clin Dent.* 1991;3(1):1–5.
16. Ahangarkani F, Khodavaisy S, Mahmoudi S, et al. Indifferent effect of NSAID analgesic ketorolac and calcium channel blocker against resistant Candida albicans. *Antimicrob Agents Chemother.* 2007;51(3):821–826.
17. Retsky M, Rogers R, Demicheli R, et al. NSAID analgesic ketorolac and calcium channel blocker against resistant Candida albicans. *Antimicrob Agents Chemother.* 2007;51(3):821–826.
18. Swerdlow SH, Campo E, Harris NL, et al. *WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.* 4th ed. Lyon: IARC; 2008:130–139.
19. Rosstein S, Bow EJ, Lavenderne M, et al. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian fluconazole prophylaxis study group. *Clin Infect Dis.* 1999;28:331–340. doi:10.1086/351528
20. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendation from an international expert panel, on behalf of the European Leukemia Net. *Blood.* 2010;115:453–474.
21. Power D, Johnsen J. *Difco TM, BBL TM, Manual: Manual of Microbiological Culture Media.* Sparks: Becton Dickinson and company; 2009.
22. Marinho SA, Teixeira AB, Santos OS, et al. Identification of Candida spp. by phenotypic tests and PCR. Braz J Microbiol. 2010;41(2):286–294. doi:10.1590/S1517-83822010000200004
23. Pincus D, Orensa S, Chatellier S. Yeast identification past present and future methods. Med Mycol. 2007;45(2):97–121. doi:10.1080/13693780601059936
24. Mannarelli BM, Kurtzman CP. Rapid identification of Candida albicans and other human pathogenic yeast by using short oligonucleotides in a PCR. J Clin Microbiol. 1998;36(1):1634–1641. doi:10.1128/JCM.36.6.1634-1641.1998
25. CLSI. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeast; Approved Guideline. M44-A2 ed. Wayne, PA: Clinical and laboratory standards Institute; 2009.
26. Ellis D. Antifungal susceptibility profile Australian antifungal susceptibility data for Candida isolates from recurrent vulvovaginal candidiasis (2007–2009) using the CLIS M44-A2 disc susceptibility standard for yeast. Mycology online. Adelaide, Australia: The University of Adelaide; 2011.
27. Meletiadis J, Mouton JW, Hamal K, Petr Guinea J; EUCAST. Subcommittee on Antifungal susceptibility testing of the ESCMID European committee for Antimicrobial susceptibility testing. Def. 2017;7(1).
28. Odds FC. Synergy, antagonism, and what the checkerboard puts between them. J Antimicrob Chemother. 2003;52(1):1. doi:10.1093/jac/dkg301
29. Ghen Y-L, Lehman VN, Averette AF, Perfect JR, Heitman J. Posaconazole exhibits In vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans. PLoS One. 2013;8(3):e57672.
30. Chau AS, Mendrick CA, Sabatelli FJ, Loebenberg D, McNicholas PM. Application of real time quantitative PCR to molecular analysis of Candida albicans strain exhibiting reduced susceptibility to azoles. Antimicrob Agents Chemother. 2004;48:2124–2131. doi:10.1128/AAC.48.6.2124-2131.2004
31. Rocha MFG, Banderia SP, De Alencar LP, et al. Azole resistance in Candida albicans from animals: highlights on efflux pump activity and gene over-expression. Mycoses. 2017;60:462–468. doi:10.1111/myc.12611
32. Pfaffi MW. A new mathematical model for relative quantification in real time PCR. Nucleic Acids Res. 2001;29(9):e45–e. doi:10.1093/nar/29.9.e45
33. Ibrahim AS, Khaled HM, Mikhail NM, Baraka H, Kamel H. Cancer Incidence in Egypt: results of the National Population –Based Cancer Registry Program. J Cancer Epidemiol. 2014;2014:1–8. doi:10.1155/2014/437971
34. Acharya UH, Kanaan MN, Cui H, Roe DJ. Does the region of diagnosis correlate with overall survival in patients with Acute Myeloid Leukemia (AML)-a SEER review of AML diagnosis from 2004–2007. Blood. 2014;124:1291. doi:10.1182/blood.V124.21.1291.1291
35. Zawam H, Salama R, Alsirafy SA, Bishr MK. Treatment outcome of Acute Myeloid Leukemia in Egypt: a developing country perspective. Int J Cancer Treat. 2018;1(1):53–59.
36. Sekeres MA, Elson P, Kalaycio ME. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113:28–36. doi:10.1182/blood-2008-05-157065
37. Donadu MG, Usai D, Marchetti M, et al. Antifungal activity of oil macerates of North Sardinia plants against Candida species isolated from clinical patients with candidiasis. Nat Prod Res. 2020;34(22):3280–3284. doi:10.1080/14786419.2018.1557175
38. Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis. 2002;2(2):73–85. doi:10.1016/S1473-3099(02)00181-0
39. Farhan MA, Moharram AM, Salah T, Shaaoban OM. Relation between antifungal resistance and enzymatic activity of yeast causing oral and vaginal mycosis. Assiut Univ J Bot Microbiol. 2019;48(1):1–16.
40. Farhan MA, Moharram AM, Salah T, Shaaoban OM. Types of yeasts that cause vulvovaginal candidiasis in chronic users of corticosteroids. Med Mycol. 2019;57(6):681–687. doi:10.1093/mmy/mmy117
41. Pfaller M, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome of Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interactive MIC breakpoint. J Clin Microbiol. 2008;46(8):2620–2629. doi:10.1128/JCM.00566-08
42. Ehrstrom S, Yu A, Rylander E. Glucose in vaginal secretion before and after oral glucose tolerance testing in women with and without recurrent vulvovaginal candidiasis. Obstet Gynecol. 2006;108(6):1432–1437. doi:10.1097/01.AOG.0000246800.38982.fc
43. Lu M, Yan H, Yu C, Yuan L, Sun S. Proton pump inhibitors act synergistically with fluconazole against resistant Candida albicans. J Infect Dev Ctries. 2013;7(1):498. doi:10.1016/S1478-6419(18)30684-3
44. Sharmar M, Biswas D, Kowal A, et al. Ibuprofen-mediated reversal of fluconazole resistance in clinical isolates of Candida. J Clin Diagn Res. 2015;9(1):DC20.
45. Usai D, Donadu M, Bua A, et al. Enhancement of antimicrobial activity of pump inhibitor associated drugs. J Infect Dev Ctries. 2019;13(02):162–164. doi:10.3855/jidc.11102
46. Tsao S, Rahkhoodaee F, Raymond M. Relative contribution of the candidate albicans ABC tr ansporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob Agents Chemother. 2009;53(4):1344–1352. doi:10.1128/AAC.00926-08
47. Holmes AR, Lin Y-H, Niimi K, et al. ABC transporters Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother. 2008;52(11):3851–3862. doi:10.1128/AAC.00463-08
48. Niimi K, Maki K, Ikeda F, et al. Overexpression of Candida albicans CDR1, CDR2, orMDR1 does not produce significant changes in echinocandin susceptibility. Antimicrob Agents Chemother. 2006;50(4):1148–1155. doi:10.1128/AAC.50.4.1148-1155.2006
49. Xiang M-J, Liu J-Y, Ni P-H, et al. Erg11 mutations associated with cross-resistance of azole–resistant Candida albicans clinical isolates. Med Mycol. 2009;47(6):695–704. doi:10.1111/j.1369-3786.2008.015706-x
50. Bannert M, Afman D, Malatino D, et al. Synergistic effects of novel antifungal agents in combination with fluconazole against fluconazole-resistant Candida albicans. J Antimicrob Chemother. 2019;74(9):2472–2479. doi:10.1093/jac/dkz174
51. Berra M, Altamura A, Toma A, et al. Antifungal activity of Verbascum thapsus L. in comparison to a commercial antifungal preparation. J Med Mycol. 2007;57(6):681–687. doi:10.1093/mmy/myy117
52. Borrero M, Ortega GC, Ulloa C, et al. Antifungal activity of some Andean medicinal plants on Candida albicans. Med Mycol. 2007;45(1):39–45. doi:10.1080/13693780601059936
53. Pressley LS, Grigsby RE, Griner EP. Yeast identification: past, present, and future methods. J Clin Microbiol. 2008;46(8):2620–2629. doi:10.1128/JCM.00566-08
54. Blaser MJ, Cohen BH, Gewirtz AT, et al. New antifungal drugs: development and clinical development. Med Mycol. 2008;46(8):2620–2629. doi:10.1128/JCM.00566-08
55. Borrero M, Ortega GC, Ulloa C, et al. Antifungal activity of some Andean medicinal plants on Candida albicans. Med Mycol. 2007;45(1):39–45. doi:10.1080/13693780601059936